15
Participants
Start Date
March 31, 2007
Primary Completion Date
September 30, 2014
Study Completion Date
October 31, 2014
MRZ 0.5 mg/m^2
NPI-0052 0.5 mg/m2 administered IV over 2 hours on Days 1, 4, 8, and 11 in each 21-day cycle
University of Maryland, Baltimore
Moffitt Cancer Center, Tampa
University of Michigan, Ann Arbor
University of Chicago, School of Medicine, Chicago
Washington University School of Medicine, St Louis
Dana Farber Cancer Institute, Boston
Lead Sponsor
Celgene
INDUSTRY